title: Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease.
abstract: This study aimed to evaluate the effects of carvedilol treatment and a regimen of supervised aerobic exercise training on quality of life and other clinical, echocardiographic, and biochemical variables in a group of client-owned dogs with chronic mitral valve disease (CMVD). Ten healthy dogs (control) and 36 CMVD dogs were studied, with the latter group divided into 3 subgroups. In addition to conventional treatment (benazepril, 0.3-0.5 mg/kg once a day, and digoxin, 0.0055 mg/kg twice daily), 13 dogs received exercise training (subgroup I; 10.3 ± 2.1 years), 10 dogs received carvedilol (0.3 mg/kg twice daily) and exercise training (subgroup II; 10.8 ± 1.7 years), and 13 dogs received only carvedilol (subgroup III; 10.9 ± 2.1 years). All drugs were administered orally. Clinical, laboratory, and Doppler echocardiographic variables were evaluated at baseline and after 3 and 6 months. Exercise training was conducted from months 3-6. The mean speed rate during training increased for both subgroups I and II (ANOVA, P>0.001), indicating improvement in physical conditioning at the end of the exercise period. Quality of life and functional class was improved for all subgroups at the end of the study. The N-terminal pro-brain natriuretic peptide (NT-proBNP) level increased in subgroup I from baseline to 3 months, but remained stable after training introduction (from 3 to 6 months). For subgroups II and III, NT-proBNP levels remained stable during the entire study. No difference was observed for the other variables between the three evaluation periods. The combination of carvedilol or exercise training with conventional treatment in CMVD dogs led to improvements in quality of life and functional class. Therefore, light walking in CMVD dogs must be encouraged.
authors.affiliation: Hospital Veterinário Sena Madureira, São Paulo, SP, BR.
authors.forename: M
authors.initials: M
authors.lastname: Marcondes-Santos
authors.affiliation: Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, BR.
authors.forename: A P
authors.initials: AP
authors.lastname: Mansur
authors.affiliation: Hospital Veterinário Sena Madureira, São Paulo, SP, BR.
authors.forename: F S
authors.initials: FS
authors.lastname: Fragata
authors.affiliation: Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, BR.
authors.forename: C M C
authors.initials: CM
authors.lastname: Strunz
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004285:Dogs; D015150:Echocardiography, Doppler / Q000662:veterinary; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate; D019344:Lactic Acid / Q000097:blood; D008297:Male; D008944:Mitral Valve Insufficiency / Q000628:therapy / Q000662:veterinary*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010805:Physical Conditioning, Animal / Q000706:statistics & numerical data*; D011412:Propanolamines / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D018709:Statistics, Nonparametric
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D010446:Peptide Fragments; D011412:Propanolamines; C109794:pro-brain natriuretic peptide (1-76); D000077261:Carvedilol; D020097:Natriuretic Peptide, Brain; D019344:Lactic Acid